Updated daily
Drug recalls
Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.
Class IITerminatedSep 23, 2015Testosterone Cypionate 250 mg/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1755-2015Class IITerminatedSep 23, 2015Testosterone Cypionate 50 mg/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1754-2015Class IITerminatedSep 23, 2015Testosterone Bi-Blend 50 mg/ml + Estradiol Valerate 2.5 mg/ml InjectableLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1753-2015Class IITerminatedSep 23, 2015Testosterone Bi-Blend 15 mg/ml +Estradiol Valerate 5 mg/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1752-2015Class IITerminatedSep 23, 2015Testosterone 87.5 mg Sterile PelletLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1751-2015Class IITerminatedSep 23, 2015Testosterone 70 mgLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1750-2015Class IITerminatedSep 23, 2015Testosterone 60 mgLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1749-2015Class IITerminatedSep 23, 2015Testosterone 37.5 mgLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1748-2015Class IITerminatedSep 23, 2015Testosterone 30 mgLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1747-2015Class IITerminatedSep 23, 2015Testosterone 25 mgLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1746-2015Class IITerminatedSep 23, 2015Testosterone 200 mgLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1745-2015Class IITerminatedSep 23, 2015Testosterone 20 mgLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1744-2015Class IITerminatedSep 23, 2015Testosterone 12.5 mgLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1743-2015Class IITerminatedSep 23, 2015Testosterone 100 mgLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1742-2015Class IITerminatedSep 23, 2015Testosterone 18 mgLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1741-2015Class IITerminatedSep 23, 2015PGE 2 (Alprostadil) 100 mcg/mlLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1740-2015Class IITerminatedSep 23, 2015MYO-DENLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1739-2015Class IITerminatedSep 23, 2015Morphine 40 mg/ml + Bupivacaine 16 mg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1738-2015Class IITerminatedSep 23, 2015Morphine 40 mg/ml + Bupivacaine 8 mg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1737-2015Class IITerminatedSep 23, 2015Morphine 30 mg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1736-2015Class IITerminatedSep 23, 2015MEGA-BURNLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1735-2015Class IITerminatedSep 23, 2015LIPOLEAN + Ascorbic Acid 50 mg/ml InjectableLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1734-2015Class IITerminatedSep 23, 2015LIPOLEAN InjectableLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1733-2015Class IITerminatedSep 23, 2015Hydromorphone 80 mg/ml + Fentanyl 15Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1732-2015Class IITerminatedSep 23, 2015Hydromorphone 80 mg/ml + Fentanyl 15Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1731-2015Class IITerminatedSep 23, 2015Hydromorphone 80 mg/ml + Clonidine 1Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1730-2015Class IITerminatedSep 23, 2015Hydromorphone 70 mg/ml+Fentanyl 16Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1729-2015Class IITerminatedSep 23, 2015Fentanyl 5Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1728-2015Class IITerminatedSep 23, 2015Betamethasone Sodium PhosphateLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1727-2015Class IITerminatedSep 23, 2015B-Complex 100 mg/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1726-2015Class IITerminatedSep 23, 2015Baclofen 2Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1725-2015Class IITerminatedSep 23, 2015Vitatrim Active InjectableLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1724-2015Class IITerminatedSep 23, 2015Vitatrim InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1723-2015Class IITerminatedSep 23, 2015Tri-MixLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1722-2015Class IITerminatedSep 23, 2015Tri-Mix InjectableLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1721-2015Class IITerminatedSep 23, 2015Tri-Mix Super InjectableLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1720-2015Class IITerminatedSep 23, 2015TRI-MIXLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1719-2015Class IITerminatedSep 23, 2015Quad-Mix 4 InjectableLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1718-2015Class IITerminatedSep 23, 2015Quad-Mix 2 InjectableLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1717-2015Class IITerminatedSep 23, 2015Quad-Mix 1 InjectableLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1716-2015